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The intracellular transport and localization of amyloid precursor protein (APP) are critical
determinants of APP processing and β-amyloid peptide production, thus crucially important
for the pathophysiology of Alzheimer’s disease (AD). Notably, the C-terminalY682ENPTY687
domain of APP binds to specific adaptors controlling APP trafficking and sorting in neurons.
Mutation on the Y682 residue to glycine (Y682G) leads to altered APP sorting in hippocam-
pal neurons that favors its accumulation in intracellular compartments and the release of
soluble APPα. Such alterations induce premature aging and learning and cognitive deficits
in APP Y682G mutant mice (APPYG/YG). Here, we report that Y682G mutation affects forma-
tion of the APP complex with sortilin-related receptor (SorLA), resulting in endo-lysosomal
dysfunctions and neuronal degeneration. Moreover, disruption of the APP/SorLA complex
changes the trafficking pathway of SorLA, with its consequent increase in secretion out-
side neurons. Mutations in the SorLA gene are a prognostic factor in AD, and changes in
SorLA levels in cerebrospinal fluid are predictive of AD in humans. These results might
open new possibilities in comprehending the role played by SorLA in its interaction with
APP and in the progression of neuronal degeneration. In addition, they further underline
the crucial role played by Y682 residue in controlling APP trafficking in neurons.
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INTRODUCTION
Amyloid precursor protein (APP) has been extensively studied for
its role as the precursor of β-amyloid peptide (Aβ) in Alzheimer’s
disease (AD). However, its physiological function still remains
largely enigmatic.
Amyloid precursor protein is a transmembrane protein that is
actively sorted among numerous compartments in the cell. After its
synthesis, the newly translated APP polypeptide undergoes several
post-translational modifications in the Golgi apparatus, including
N- and O-glycosylation, sulfation, phosphorylation, and palmi-
toylation (Guo et al., 2012a; Jiang et al., 2014). Mature APP is
then trafficked to the cell surface. Once APP reaches the cell sur-
face, it is rapidly internalized and subsequently trafficked through
endocytic and recycling compartments back to the cell surface
or degraded in the lysosome (Guo et al., 2012a; Jiang et al.,
2014).
Abbreviations: Aβ, amyloid beta; APP, amyloid precursor protein; CTF, car-
boxyl terminal fragment; EEA1, early endosome-associated protein 1; Lamp1,
lysosomal-associated membrane protein 1; sAPPα, soluble amyloid precursor pro-
tein alpha; sAPPβ, soluble amyloid precursor protein beta; IF, immunofluorescence;
IP, immunoprecipitation; SorLA, sortilin-related receptor; TL, total lysate; WB,
western blot; WT, wildtype; YG, mutated amyloid precursor protein: APP Y682G.
Amyloid precursor protein trafficking in neurons is largely
controlled by the Y682ENPTY687 domain via its specific binding
to numerous cytosolic adaptor proteins (Russo et al., 2002; Tarr
et al., 2002; Zhou et al., 2004, 2009; Tamayev et al., 2009; Muller
and Zheng, 2012). In particular (tyrosine-682), Y682 modulates
the interaction with adaptor proteins through its phosphorylation
and dephosphorylation, suggesting that this residue functions as a
switch that activates certain APP signaling pathways (Russo et al.,
2002; Tarr et al., 2002; Zhou et al., 2004, 2009; Tamayev et al., 2009;
Muller and Zheng, 2012). Relevantly, the trafficking of APP affects
two competitive enzymatic APP processing pathways, mediated
by α- and β-secretases. Notably, an imbalance to the β-secretase-
mediated cleavage of APP leads to the accumulation of neurotoxic
fragments, including Aβpeptide,which is considered a major cause
of AD (Guo et al., 2012a; Jiang et al., 2014).
We previously reported that substituting Y682 with a glycine
in knock-in animals (APPYG/YG) promotes a premature, age-
dependent decline in cognition, learning, and locomotor perfor-
mance (Matrone et al., 2012). The Y682G mutation induces a
redistribution of APP inside neurons and its concomitant accu-
mulation in intracellular compartments (Barbagallo et al., 2010;
Matrone et al., 2011; Matrone, 2013). Additionally, the lysosome
area is enlarged, and the number of lysosomes is significantly
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decreased in dorsal root ganglia and fibroblasts from APPYG/YG
mice (Basso and Matrone, 2013; Matrone, 2013).
We believe that Y682 plays a crucial role in APP trafficking by
possibly controlling APP binding to adaptors and consequently
preventing alteration in its cleavage and sorting, finally resulting
in neuronal degeneration and death.
Notably, aberrant APP trafficking and deficits in the endo-
lysosomal system have been largely described as early causes of
neurodegeneration and AD (Nixon et al., 2005; Yu et al., 2005;
Lee and Landreth, 2010; Nixon and Yang, 2011). Additionally,
aging, a major risk factor for AD, is also associated with defects
in autophagocytosis (Cuervo, 2008; Salminen and Kaarniranta,
2009).
Here, we report that Y682G mutation induces alternative APP
trafficking toward late endosomes (LEs) and lysosomes, ensu-
ing functional alterations of the lysosomal system. Additionally,
sortilin-related receptor (SorLA), which controls the trafficking of
APP between the trans-Golgi network (TGN) and early endosomes
(EEs) by interacting with specific cytosolic adaptors (Willnow and
Andersen, 2013), fails to bind mutated APP and is largely secreted
outside neurons. Notably, defects in the binding of SorLA and its
interacting adaptors are considered important risk factors for AD
(Guo et al., 2012b).
These results underline the relevance of residue Y682 in control-
ling APP trafficking and sorting in neurons by likely interacting
with SorLA. In addition, they further emphasize the role of SorLA
as a potential target protein to monitor APP activity in neurons.
Finally, they point to the importance of identification of further
adaptors to better understand the molecular events described here.
RESULTS
MUTATED APP IS SORTED TO THE LYSOSOME AND LATE ENDOSOME
To analyze the role of Y682 in controlling APP trafficking and sort-
ing, we first determined the cellular compartment where mutated
APP is preferentially localized using hippocampal neurons from
APPYG/YG and control mice.
We previously reported the accumulation of APP in intracel-
lular compartments and alterations in the number and size of
lysosomes from APPYG/YG neurons (Matrone et al., 2011, 2012).
Caster et al. recently reported that APP mutation on Y682 preferen-
tially accumulated in lysosomes from HeLa cells (Caster and Kahn,
2013). Therefore, we began our analysis by focusing on the endo-
lysosomal compartments of hippocampal neurons from wildtype
(WT) and APPYG/YG mice.
We performed confocal microscopy of neurons that were
stained with antibodies against APP and either lysosomal-
associated membrane protein 1 (Lamp1) or Rab7 (Figure 1). We
found an augmented overlap between the localization of APP (red)
and Lamp1 (green) in APPYG/YG neurons (YG) compared with WT
cells (Figure 1I). We also detected an increase in the co-localization
between APP and Rab7, a marker of the LE (Figure 1R).
This increase in APP localization inside Lamp1- and Rab7-
positive vesicles suggested that the Y682G mutation disturbed the
recycling of APP to the plasma membrane (PM), triggering its
accumulation in endo-lysosomal compartments.
We next examined whether APP trafficking to the EE and Golgi
compartment was also altered in APPYG/YG neurons. Interestingly,
immunostaining for EEA1, a marker of EEs, indicated a reduc-
tion of co-localization with mutated APP in hippocampal neurons
(Figures 2A–I). Similarly,APP localization in Golgi compartments
that were positive for (Figures 2M,Q,R) Giantin was also reduced
by the Y682G mutation (Figures 2J–R).
Y682 MUTATION AFFECTS LYSOSOMAL ACTIVITY IN HIPPOCAMPAL YG
NEURONS
We next investigated whether the observed accumulation of APP
in Lamp1-positive vesicles leads to a defect in lysosomal activ-
ity. To test for lysosomal activity, we used western blotting (WB)
to detect the conversion of immature to mature cathepsin D
(CD), a lysosomal protease that is used as an indirect marker
of lysosomal function (Luzio et al., 2007). The WB analysis of
homogenates from WT and APPYG/YG neurons showed a signifi-
cant decrease in the level of the two CD active fragments, which
migrate at 32 and 14 kDa (CDm; Figures 3A,B). Furthermore, the
enzymatic activity of CD and cathepsin B (CB) confirmed a sig-
nificant reduction of lysosomal activity in neurons isolated from
APPYG/YG mice (Figure 3C). These data clearly suggest impair-
ment in the lysosomal machinery and a key role played by the
Y682ENPTY687 domain in controlling APP trafficking in neu-
rons and preventing lysosomal dysfunction. These results are also
interesting when considering that a reduction of CD activity has
been previously reported in brains from AD patients (Yang et al.,
2011).
Y682G MUTATION AFFECTS APP BINDING TO SorLA AND INCREASES
SorLA SECRETION OUTSIDE NEURONS
The Y682ENPTY687 motif within the APP cytoplasmic domain
plays a crucial role in the sorting and trafficking of APP through
its binding to specific adaptor proteins. The recruitment of specific
adaptors to APP is linked to its routing throughout the endomem-
brane system and its phosphorylation state, particularly the Y682
residue (Russo et al., 2002; Tarr et al., 2002; Zhou et al., 2004, 2009;
Tamayev et al., 2009; Muller and Zheng, 2012).
The Vps10p-D receptor, SorLA, is a neuronal protein that shut-
tles from the PM to endosomes and TGN and regulates the traffick-
ing and processing of APP (Andersen et al., 2005). SorLA confines
APP to the Golgi apparatus and affects its transition to the cell
surface, a step that is crucial for conversion to both soluble APPα
(sAPPα) and sAPPβ/Aβ (Andersen et al., 2005, 2006; Dodson et al.,
2008; Fjorback et al., 2012). We observed the enhancement of
mutated APP trafficking to Rab7-positive vesicles and sought to
determine whether Y682G substitution impairs the binding of APP
to SorLA.
Confocal microscopy of hippocampal neurons that were
immunostained for APP and SorLA showed a strong co-
localization between SorLA and APP in WT cells (Figures 4A–
D). However, such co-localization was significantly reduced
in APPYG/YG neurons (Figures 4E–H). Interestingly, confocal
microscopy analysis indicated a decrease in SorLA in the cell body
and an increase along the neurites of Y682G neurons (Figure 4).
Consistent with the reduced co-localization, co-immuno
precipitation (co-IP) experiments from the hippocampi of WT
and APPYG/YG mice showed a reduced complex formation between
APP and SorLA in APPYG/YG neurons (Figures 4J,K).
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FIGURE 1 | Amyloid precursor protein increases in LAMP1- and
Rab7-positive vesicles. (A–G) Confocal microscopy analysis of
double-staining of mouse anti-APP [red; (A,E)] and rabbit anti-Lamp1 [green;
(B,F)] in WT and APPYG/YG (YG) hippocampal neurons [(A–D) and
(E–H), respectively; 63× objective). Scale bars=10µm. The panels are
representative of five different experiments performed in duplicate.
[(C,G) and (D,H)] Co-localization analysis of WT and APPYG/YG hippocampal
neurons. The analysis was performed using Zen/Zeiss software. Notice that
the area of overlap between APP and Lamp1 immunostaining (white) was
significantly increased in APPYG/YG mice (H) compared with WT (D). (D,H) High
magnification of (C,G). The (R) coefficient (Pearson’s coefficient) was used for
the quantitative and comparative analyses (I). The data are expressed as
mean±SEM. n=10. *p<0.05. (J–P) Confocal microscopy analysis of
double-staining for mouse anti-APP [red; (J,N)] and rabbit anti-Rab7 [green;
(K,O)] in WT and APPYG/YG (YG) hippocampal neurons [(J–M) and
(N–Q), respectively; 63× objective]. Scale bars=10µm. The panels are
representative of four different experiments performed in duplicate. [(L,P) and
(M,Q)] Co-localization analysis of WT and APPYG/YG hippocampal neurons. The
analysis was performed using Zen software. Notice that the area of overlap
between APP and Rab7 immunostaining (white) was significantly increased in
APPYG/YG mice (Q) compared with WT (M). (M,Q) High magnification of
(L,P). The (R) coefficient (Pearson’s coefficient) was used for the quantitative
and comparative analyses (R). The data are expressed as mean±SEM. n=8.
*p<0.05.
The way in which Y682 mutation disturbs the binding of SorLA
to APP is still unknown. One plausible mechanism is that some
adaptor proteins may fail to bind APP or SorLA, resulting in
alterations of the APP/SorLA complex.
Sortilin-related receptor has been largely described as a poten-
tial tool that is predictive of the progression of AD in humans. In
fact, the levels of SorLA appeared to be reduced in AD brain tis-
sues and increased in cerebrospinal fluid (Ikeuchi et al., 2010; Guo
et al., 2012b). Therefore, we hypothesized that the lack of forma-
tion of the APP/SorLA complex might result in the missorting of
SorLA and its secretion outside neurons. To test this hypothesis, we
analyzed the protein levels of SorLA in both soluble and insoluble
hippocampal fractions from APPYG/YG mice and relative controls
(Figures 4L,M). As expected, SorLA levels in the soluble frac-
tion from APPYG/YG tissue was significantly increased, whereas
its levels appeared to be reduced in the corresponding insoluble
fraction (Figures 4L,M). The increased secretion of SorLA from
APPYG/YG neurons was further analyzed in the medium of primary
hippocampal neurons. Also here, the amount of SorLA released
from APPYG/YG neurons into the medium was greatly increased
when compared to the control samples (Figures 4O,P). Such
increase was paralleled by an intensification of sAPPα amount
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FIGURE 2 | Amyloid precursor protein decreases in Golgi
compartment and early endosomes. (A–G) Confocal microscopy
analysis of double-staining for rabbit anti-APP red; (A,E)] and mouse
anti-EEA1 [green; (B,F)] in WT and APPYG/YG (YG) hippocampal neurons
[(A–D) and (E–H), respectively; 63× objective]. Scale bars=7µm. The
panels are representative of three different experiments performed in
duplicate. (C,G) and (D,H) Co-localization analysis of WT and APPYG/YG
hippocampal neurons. The analysis was performed using Zen software.
Notice that the area of overlap between APP and EEA1 immunostaining
(white) was significantly decreased in APPYG/YG mice (H) compared with
WT (D). The R coefficient (Pearson’s coefficient) was used for the
quantitative and comparative analyses (I). The data are expressed as
mean±SEM. n= 6. **p<0.001. (J,P) Confocal microscopy analysis of
double-staining for rabbit anti-APP [red; (J,N)] and mouse anti-giantin
[green; (K,O)] in WT and APPYG/YG (YG) hippocampal neurons [(J–L) and
(N–P), respectively; 63× objective]. Scale bars=5µm. The panels are
representative of five different experiments performed in duplicate.
(L,P) and (M,Q) Co-localization analysis of WT and APPYG/YG hippocampal
neurons. The analysis was performed using Zen software. The
(R) coefficient (Pearson’s coefficient) was used for the quantitative and
comparative analyses (R). The data are expressed as mean±SEM.
n=10. **p< 0.01.
in the medium of APPYG/YG neurons. Consistently, the corre-
sponding SorLA intracellular levels appeared significantly reduced
(Figure 4N). Notably and consistent with the evidence that Y682G
mutation induces a preferential α-secretase-mediated APP cleav-
age (Basso and Matrone, 2013), WB analysis performed with
anti-sAPPα antibody showed an increase in sAPPα in APPYG/YG
neurons (Figure 4N).
DISCUSSION
Altogether, our data further elucidate the role played by the
Y682ENPTY687 domain in controlling APP trafficking and sort-
ing in neurons. Our data support a model whereby alterations
in the binding of APP to SorLA likely leads to an aberrant
misrouting of APP in hippocampal neurons, resulting in APP
accumulation in endo-lysosomal compartments and autophagic
defects (see Box 1).
The intracellular portion of APP, which encompasses the
Y682ENPTY687 sequence of AICD, has been reported to interact
with several different adaptors. Y682ENPTY687 plays a crucial role
in modulating the binding and unbinding of APP to specific adap-
tor proteins via phosphorylation and dephosphorylation of the
Y682 residues. When Y682 is phosphorylated, it creates docking sites
for cytosolic proteins, such as Shc, Grb2, and Grb7, and inhibits
the binding of others, such as the Fe65 family. Differently, when
Y682 is dephosphorylated, the binding of proteins containing a
phosphotyrosine-binding (PTB) domain is impaired (Russo et al.,
2002; Tarr et al., 2002; Zhou et al., 2004, 2009; Tamayev et al., 2009;
Muller and Zheng, 2012).
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FIGURE 3 | Lysosome activity is impaired in APPYG/YG hippocampal
neurons. (A) Western blot analysis of cathepsin D in hippocampi from WT
and APPYG/YG (YG) mice and (B) the corresponding densitometric analysis.
The data were normalized to the corresponding GADPH values. The optical
density (OD) is expressed as a percentage (mean±SEM) of the proCD
values from WT samples. n=3. *p<0.05. (C) Cathepsin D (CD) and
cathepsin B (CB) cysteine protease activity in WT and APPYG/YG (YG)
hippocampal neurons. The samples were collected and analyzed according
to the procedure suggested by the manufacturer and described in the
Section “Materials and Methods.” The relative activity is expressed as
fluorescent units (FU)/mg protein. The data are expressed as mean±SEM.
n=3. *p<0.05.
Here, we report that when Y682 residue is mutated (Y682G
mutation), APP is misrouted to the LEs/lysosomes, triggering
lysosomal defects and contributing to progressive and premature
aging and the neurodegenerative phenotype previously reported
in YG knock-in mice (Matrone et al., 2012).
In addition, we provide clear evidence of the role played by Y682
in the interaction of APP with SorLA, and we speculate on the pos-
sibility that the lack of a proper interaction between SorLA and
APP could lead to the misrouting of APP in neurons and conse-
quently to the lysosomal defects previously observed in APPYG/YG
mice (Matrone et al., 2012). Interestingly, the lack of APP and
SorLA interaction also results in increased secretion of SorLA into
the soluble fraction of APPYG/YG brains and into the medium of
cultured hippocampal APPYG/YG neurons.
The role of SorLA in controlling APP trafficking has been pre-
viously clarified (Andersen et al., 2005). SorLA directly binds APP
and controls APP trafficking from EEs back to the TGN or PM,
thus preventing β- and α-secretase-mediated APP cleavage.
The complexity in the APP and SorLA interaction has been
previously predicted in the SorLA-null mouse model and in
several SorLA-overexpressing cell lines (Andersen et al., 2005;
Spoelgen et al., 2006; Schmidt et al., 2012; Mehmedbasic et al.,
2015). All these studies have allowed the identification of numer-
ous putative SorLA binding sites on both the N- and C-terminal
sequences of APP depending on the cellular context, point-
ing to the possibility that APP interacts with SorLA at multi-
ple sites and that such interaction probably requires the addi-
tional collaboration of other adaptors (Andersen et al., 2005;
Spoelgen et al., 2006; Schmidt et al., 2012; Mehmedbasic et al.,
2015).
Accordingly, we report here that the alteration in APP binding
to SorLA (and likely to other adaptors) leads to APP accumulation
in LEs and lysosomes and to autophagic defects, which are
considered a major risk factor for AD and dementia during aging
(Cuervo, 2008; Salminen and Kaarniranta, 2009).
In addition, evidence from pathophysiological and genetic
studies clearly suggests that SorLA plays a crucial role in AD-related
processes. Several studies of brain or cerebrospinal fluid specimens
have reported alterations in the levels of SorLA in the brains of
some individuals with sporadic AD (Ma et al., 2009; Ikeuchi et al.,
2010). Moreover, several mutations of the SorLA gene have been
associated with AD (Rogaeva et al., 2007; Alexopoulos et al., 2011;
Caglayan et al., 2014).
Based on the critical phenotype previously observed in
APPYG/YG mice, which resulted in premature aging and cogni-
tive and learning deficits (Matrone et al., 2011, 2012), and the
potential role of SorLA as a predictive factor of neurodegenera-
tion in AD patients (Rogaeva et al., 2007; Alexopoulos et al., 2011;
Caglayan et al., 2014), we believe that these results strongly under-
score the relevance of the correct APP binding to adaptor proteins,
via Y682ENPTY687 domain, as a future potential strategy to prevent
neurodegeneration in vivo.
MATERIALS AND METHODS
ANIMAL MODEL
Male homozygous APP Y682G mice (APPYG/YG) and WT con-
trols (C57BL/6J, approximately 30–40 days of age) were used
in this study. The APPYG/YG mice were a generous gift from
Prof. D’Adamio and have been previously described in detail
(Barbagallo et al., 2010, 2011; Matrone et al., 2011, 2012;
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FIGURE 4 |Y682G mutation prevents binding of APP to SorLA and
increases SorLA secretion. (A–H) Confocal microscopy analysis of
double-staining for rabbit anti-SorLA [green; (A,E)] and mouse anti-APP [red;
(B,F)] in WT and APPYG/YG (YG) hippocampal neurons [(A–C) and
(E–G), respectively; 63× objective]. Scale bars=7µm. (D,H) high
magnification of the (C) and (G), respectively. Co-localization analysis was
performed using Zen software (I). The panels are representative of seven
different experiments. (G) Quantitative analysis was performed by comparing
the R coefficient (Pearson’s coefficient) between WT and APPYG/YG (YG)
neurons. n=7. *p<0.05. (J,K). Protein samples from hippocampi from either
WT or APPYG/YG (YG) mice were immunoprecipitated with mouse anti-α-SorLA
antibody (co-IP SorLA) and analyzed with rabbit anti-APP. TL, total lysate; IP,
immunoprecipitate. The same membrane was stripped and analyzed with
mouse anti-SorLA. (L,M) SorLA WB analysis in the soluble and insoluble
fractions from hippocampal tissues from WT and APPYG/YG (YG) mice. As
positive and negative controls for the fractionations, we used HSC70 protein
and Lamp1, respectively. The optical density analysis is reported below. Data
from the soluble (Sol) and insoluble (Unsol) fractions were normalized to the
corresponding HSC70 and Lamp1 values and are expressed as a percentage
of WT (n=4). *p<0.05 vs. WT (Newman–Keuls test). (N) WB analysis of APP,
sAPPα, and sSorLA from hippocampal primary neuronal cultures of WT and
APPYG/YG (YG) mice (O) Medium collected from APPYG/YG (YG) neurons and the
corresponding control (WT) samples were analyzed by WB for sAPPα and
sSorLA (see Materials and Methods). WB is representative of three different
experiments. (P) Densitometric analysis of (N,O). Black histogram: WT; Gray
histogram: YG. (N =3; Newman–Keuls test) *p<0.05 vs. WT.
Basso and Matrone, 2013; Matrone, 2013). The mice from both
lines were bred and group-housed in the Lab Animal Centre of
Taconic (Ejby, DK) at an ambient temperature of 22–23°C and on
a 12/12 h dark/light cycle (lights on 7 a.m.).
All of the mice were anesthetized by 2-bromo-2-chloro-
1,1,1-trifluoroethane inhalation and euthanized in accordance
with international guidelines on the ethical use of animals
(European Communities Council Directive of November 24, 1986;
86/609/EEC) and Danish guidelines. The brains were quickly
removed from the skulls, and the hippocampi were dissected on
ice according to the procedure previously described by La Rosa
et al. (2013).
We previously reported that neuronal decline in APPYG/YG mice
starts to be evident at 3 months (Matrone et al., 2012), for this
reason all of the experiments reported herein were performed in
3-month-old APPYG/YG and control mice.
IMMUNOPRECIPITATION
For the IP reactions, protein samples were added to Dynabeads-
Protein G (30µg/100µl) according to the procedure described
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Box 1 Y682G mutation alters APP trafficking and leads to an increase in SorLA secretion.
(A) In normal neurons, SorLA (green) controls APP (blue–yellow) trafficking from early endosome (EE) back to the trans-Golgi network
(TGN) or plasma membrane (PM). (B) Because of the Y682G mutation on the Y682ENPTY687 domain of APP (YG), SorLA is no longer able
to interact with mutated APP (blue–red); consequently, mutated APP mislocalizes to the late endosome (LE) and lysosome (LS) where it
is likely processed to generate CTF peptides (Basso and Matrone, 2013). The accumulation of APP in the late endosome and lysosomes
induces alterations in lysosomal activity and leads to the neuronal defects that were previously reported in APPYG/YG mice (YG) (Matrone,
2013). As a result of the lack of binding to APP, SorLA is trafficked to the plasma membrane where it is rapidly cleaved and secreted outside
neurons.
by the manufacturer (Invitrogen, Naerum, Denmark) and eluted
with 0.1 M citrate buffer (pH 2.3).
For the IP analysis, we used anti-mouse anti-SorLA from
Abcam [mouse monoclonal (3B6B11) to SorLA]. The WB analysis
was performed using rabbit anti-APP antibody (clone Y188) from
Abcam.
WESTERN BLOT ANALYSIS
Whole mouse brain was sonicated in a buffer containing 20 mM
Tris-base pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA plus
protease (Roche, Complete) and phosphatase inhibitors.
To obtain soluble and insoluble fractions, the lysates were first
spun at 1,000× g for 15 min and then for an additional 4 h at
100,000× g. The soluble fraction was separated from the pellet
and analyzed by WB. Equal amounts (30µg) of proteins were sep-
arated on 4–12% Bis-Tris SDS-PAGE gels (Invitrogen, DK), blotted
onto nitrocellulose membranes (Amersham, DK), and incubated
overnight with the appropriate primary antibody. We used rabbit
anti-cathepsin D and rabbit anti-Lamp1 from Santa Cruz (Santa
Cruz,CA,USA,DK); mouse anti-SorLA (clone 3B6B11) and rabbit
anti-APP (clone Y188) from Abcam (Abcam, UK).
Media collected from APPYG/YG neurons and the correspon-
dent control samples were centrifuged at 10,000× g for 30 min to
remove cell debris, and the supernatant was further centrifuged
at 100,000× g for 12 h at 4°C. The pellets were solubilized in
2% SDS-loading buffer and analyzed by WB for sAPPα and
sSorLA. To detect α-secretase-mediated APP cleaved peptides, we
used anti α-APP (MyBioSource, clone MBS533522). An antibody
against the N-terminal domain of SorLA (sc33822) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) was used to assess
the amount of SorLA released into the medium and retained in
neurons.
PRIMARY HIPPOCAMPAL NEURONAL CULTURES
Hippocampal neurons were prepared from embryonic day
17/18 (E17/18) mice as previously reported (Matrone et al.,
2008, 2009). The hippocampi were dissected in Hank’s Bal-
anced Salt Solution buffered with HEPES and dissociated via
trypsin/ethylenediaminetetraacetic acid treatment. A total of
106 cells were plated on 3.5-cm dishes that were precoated with
poly-l-lysine. After 2 days of culture in neurobasal medium that
contained B-27 supplement and Glutamax, cytosine arabinofura-
noside was added to reduce glial proliferation.
CONFOCAL MICROSCOPY AND CO-LOCALIZATION ANALYSIS
The neurons were fixed for 20 min in phosphate-buffered saline
(PBS) that contained 4% formaldehyde, permeabilized with 0.05%
Triton (5–10 min for 20°C), and processed for double-labeling
with the appropriate antibodies. Secondary antibodies coupled to
Alexa dyes (488 or 594) were obtained from Abcam (Cambridge,
UK). The nuclei were visualized by staining with DAPI (1µg/ml;
Sigma Brøndby, Denmark). Digital images were obtained with a
Zeiss LSM confocal lsm780 system using 63× oil NA 1.3 objective.
Quantification of the co-localization experiments was performed
using Zen 2009 software. Pearson coefficients (R coefficients) were
used as co-localization coefficients.
For the immunofluorescence analysis, we used rabbit anti-
Lamp1 (sc199992), rabbit anti-APP (clone Y188), mouse
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anti-Rab7 (Rab7-117), mouse anti-EEA1 [anti-EEA1 antibody
(1G11); EE marker], and mouse anti-giantin (clone 9B6), from
Abcam. For the experiments reported in Figures 4A–H,N,O we
used anti α-APP (MyBioSource, clone MBS533522) and anti-
SorLA (sc33822) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
MEASUREMENT OF CATHEPSIN D AND B ACTIVITY
Enzymatic CD and CB activity was examined in hippocampal
tissues from WT and YG mice using a CD or CB activity assay
kit (Abcam). Briefly, tissues were washed twice in ice-cold PBS
and then homogenized in extraction buffer. After 10 min incuba-
tion on ice, the extract was centrifuged at 10,000× g for 5 min,
and 50µl of the supernatant was mixed with an equal volume
of 2× reaction buffer and 2µl substrate (GKPIFFRLK[Dnp]-DR-
NH2-MCA substrate for CD or 10 mM Ac-RR-AFC substrate for
CB) in a 96-well microplate. The plates were kept in the dark at
37°C for 1 h, and fluorescence was recorded using a FLUOstar
Optima plate reader (BMG Labtech, Milan, Italy). The protein
concentration was determined by the BCA method (Bio-Rad Lab-
oratories, Hercules, CA, USA) at 328 and 460 nm excitation and
emission wavelengths, respectively, for CD activity or 400 and
505 nm excitation and emission wavelengths for CB activity.
STATISTICAL ANALYSIS
The statistical analysis was performed using two-tailed t -tests, and
multiple comparisons were made using one-way, two-way, or two-
way repeated-measures analysis of variance (ANOVA) followed by
a post hoc test using GraphPad Prism 6 software (San Diego, CA,
USA). Statistical significance was accepted at the 95% confidence
level (p< 0.05).
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